在CREATE随机试验中采访1型糖尿病的毛利土著人,使用开源自动化胰岛素输送
Mercedes Burnside1, Tracy Haitana2, Hamish Crocket3
1Christchurch, New Zealand Department of Paediatrics, University of Otago.
Journal of diabetes and metabolic disorders
|May 30, 2023
概括
患有1型糖尿病 (T1D) 的毛利原住民发现开源自动化胰岛素输送 (AID) 赋权,尽管存在系统性障碍. 提出了解决方案,以改善毛利人平等获得糖尿病技术的机会.
科学领域:
- 糖尿病 技术 技术
- 健康 公平 卫生 公平
- 土著健康土著健康
背景情况:
- 开源自动化胰岛素输送 (AID) 系统被1型糖尿病 (T1D) 患者广泛使用.
- 在边缘化种族群体,特别是原住民毛利人中,AID系统的通用性和公平性仍然未被充分探索.
- 了解参与者的经验对于解决T1D管理中的健康差异至关重要.
研究的目的:
- 在CREATE试验中探索使用开源AID系统的原住民毛利参与者的经验.
- 识别在T1D的毛利人中使用AID的背景下,促进健康公平的推动者和障碍者.
- 为了改善健康结果,为糖尿病服务的重新设计提供信息.
主要方法:
- 一个使用Kaupapa Māori研究方法的定性子研究.
- 与毛利参与者 (儿童和成年人) 和他们的 whānau (大家庭) 进行了十次半结构化采访.
- 在转录的采访数据上进行了主题分析,使用NVivo软件进行编码.
主要成果:
- 参与者报告了一种赋权感,改善了生活质量,福祉和血糖控制.
- 父母感到放心,而孩子则获得了更大的独立性.
- 强调了易于使用和适应 whānau 的需求,并解决了可管理的技术问题.
- 参与者确定了阻碍毛利人平等获得糖尿病技术的系统性健康结构.
结论:
- 原住民毛利参与者报告了积极的经验和继续使用开源AID的愿望.
- 确定了公平获取和利用的重大结构性和社会经济障碍.
- 为重新设计糖尿病服务提出了基于力量的解决方案,以提高T1D的毛利人的健康公平.
相关概念视频
Diabetes Mellitus: Overview and Type I Subtype
2.8K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.8K
Diabetes Mellitus: Type 2 and Gestational
2.6K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.6K
Insulin Formulations: Types and Delivery
239
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
239
Diabetes: Management and Pharmacotherapy
319
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
319
Insulin: Dosing Regimen and Adverse Effects
217
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
217


